Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study
Authors:
- David MichonneauDMDavid Michonneau
- Raynier DevillierRDRaynier Devillier
- Mikko KeränenMKMikko Keränen
- Marie Thérèse RubioMRMarie Thérèse Rubio
- Malin NicklassonMNMalin Nicklasson
- Hélène Labussière-WalletHLHélène Labussière-Wallet
- Martin CarreMCMartin Carre
- Anne HuynhAHAnne Huynh
- Elisabet ViaynaEVElisabet Viayna
- Montserrat RosetMRMontserrat Roset
- Jonathan FinziJFJonathan Finzi
- Minja PfeifferMPMinja Pfeiffer
Open Access
- 6 May 2024
- journal article
- research article
- Published by MDPI AG in Hematology Reports
- Vol. 16 (2) , 283-294
Abstract
Acute graft-versus-host disease (aGVHD) remains a barrier to successful allogeneic hematopoietic stem cell transplantation (HSCT) outcomes. Contemporary comprehensive analyses of real-world clinical outcomes among patients who develop aGVHD post-HSCT are needed to better understand the unmet needs of this patient population. This multicenter, retrospective chart review describes treatment patterns and clinical outcomes among patients (≥18 years old) from Finland, Sweden, and France who developed grades II–IV aGVHD after their first HSCT (January 2016–June 2017). From 13 participating centers, 151 patients were included. The median (Q1, Q3) age at HSCT was 56 (45, 62) years old. One line of aGVHD treatment was received by 47.7%, and the most common first-line treatment was methylprednisolone (alone or in a combination regimen, 74.2%; monotherapy, 25.8%). Among patients treated with methylprednisolone, 79.5% achieved a complete or partial response. The median (Q1, Q3) number of treatment lines was 2.0 (1.0, 3.0). The median (Q1, Q3) time to obtain an aGVHD diagnosis from transplant was 29.5 (21.0, 44.0) days, and 14.5 (7.0, 34.0) days to achieve the best response for 110 evaluable patients. At 6 and 12 months, 53.6% and 49.0%, respectively, achieved a complete response. Chronic GVHD occurred in 37.7% of patients, and aGVHD reoccurred in 26.5%. Following aGVHD diagnosis, mortality rates were 30.0% at 6 months and 37.3% at 12 months. Findings from this study demonstrate a continuing unmet need for new therapies that control aGVHD and improve mortality.Keywords
Funding Information
- Incyte (Wilmington, DE, USA)
This publication has 23 references indexed in Scilit:
- Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data studySupportive Care in Cancer, 2022
- Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2020
- Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2019
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019Bone Marrow Transplantation, 2019
- Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database AnalysisTransplantation and Cellular Therapy, 2019
- The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapiesBone Marrow Transplantation, 2019
- EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessmentBone Marrow Transplantation, 2018
- Use of Real-World Evidence to Characterize Clinical Outcomes in Patients Who Develop Acute Graft Versus Host Disease Undergoing Allogeneic Stem Cell Transplantation in the United StatesTransplantation and Cellular Therapy, 2018
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Graft-versus-host diseaseThe Lancet, 2009